AFM13 
GtoPdb Ligand ID: 10067
|
Synonyms: AFM 13 | AFM-13
Compound class:
Antibody
Comment: AFM13 is a tetravalent bispecific anti-CD30/CD16A tandem diabody that is constructed solely from Fv domains [1]. It is being developed by Affimed as a novel NK cell-engaging immuno-oncology therapeutic for the treatment of CD30-expressing malignancies. AFM13 simultaneously binds CD30 on Hodgkin's lymphoma cells and CD16A (FcγRIIIA) on NK cells, and acts to selectively recruit NK cells immune effector cells to destroy the cancer cells. AFM's mechanism of action differs from that of the anti-CD30 antibody-drug conjugate brentuximab vedotin, and it was found to be active in brentuximab vedotin-refractory patients in Phase 1 trial [2].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| Immunopharmacology Comments |
| AFM13 actively recruits NK cells (by binding CD16A on their surface) selectively to Hodgkin's lymphoma cells (by binding CD30 on these cancer cells) to destroy the cancer cells [1]. AFM13 is a Phase 2 clinical immuno-oncology candidate. |
| Immunopharmacology Disease | |||
| Disease | X-Refs | Comment | References |
| Lymphoma, Hodgkin, Classic; CHL |
Disease Ontology:
DOID:8567 OMIM: 236000 |
Phase 2 clinical candidate for relapsed/refractory Hodgkin lymphoma- see NCT02321592 | |
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License